

# Targeted Therapy in the Management of Advanced Gastric Cancer in the Era of Personalized Medicine?

Oncologist

17, 346-358

DOI: [10.1634/theoncologist.2011-0311](https://doi.org/10.1634/theoncologist.2011-0311)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Combined features based on MT1-MMP expression, CD11b <sup>+</sup> immunocytes density and LNR predict clinical outcomes of gastric cancer. <i>Journal of Translational Medicine</i> , 2013, 11, 153.	1.8	27
3	LAT-1 functions as a promotor in gastric cancer associated with clinicopathologic features. <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 693-699.	2.5	24
4	Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?. <i>Therapeutic Advances in Gastroenterology</i> , 2013, 6, 15-31.	1.4	43
5	The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere. <i>Journal of Translational Medicine</i> , 2013, 11, 241.	1.8	64
6	Gastric cancer's molecular and clinical dimensions. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 643-655.	12.5	376
7	Metastatic gastric cancer treatment: a little slow but worthy progress. <i>Medical Oncology</i> , 2013, 30, 464.	1.2	32
8	Pilot Studies for Personalized Cancer Medicine: Focusing on the Patient for Treatment Selection. <i>Oncologist</i> , 2013, 18, 1180-1188.	1.9	22
9	Ramucirumab: a novel antiangiogenic agent. <i>Future Oncology</i> , 2013, 9, 789-795.	1.1	32
10	The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer. <i>International Journal of Oncology</i> , 2013, 43, 1627-1635.	1.4	30
11	<i>Helicobacter pylori</i> Infection Predicts Favorable Outcome in Patients with Gastric Cancer. <i>Current Oncology</i> , 2013, 20, 388-395.	0.9	22
14	Pathogenetic mechanisms in gastric cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 13804.	1.4	81
15	How Prognostic and Predictive Biomarkers Are Transforming Our Understanding and Management of Advanced Gastric Cancer. <i>Oncologist</i> , 2014, 19, 1046-1055.	1.9	20
16	Lin28 promotes Her2 expression and Lin28/Her2 predicts poorer survival in gastric cancer. <i>Tumor Biology</i> , 2014, 35, 11513-11521.	0.8	14
17	Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review). <i>Molecular and Clinical Oncology</i> , 2014, 2, 175-181.	0.4	48
18	The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma. <i>Cancers</i> , 2014, 6, 1441-1463.	1.7	167
19	The use of lipid-coated nanodiamond to improve bioavailability and efficacy of sorafenib in resisting metastasis of gastric cancer. <i>Biomaterials</i> , 2014, 35, 4565-4572.	5.7	101
20	The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 925-942.	1.9	32
21	WAVE3 promotes epithelial-mesenchymal transition of gastric cancer through upregulation of Snail. <i>Cancer Gene Therapy</i> , 2014, 21, 499-506.	2.2	12

#	ARTICLE	IF	CITATIONS
22	HER2/neu-directed therapy for biliary tract cancer. <i>Journal of Hematology and Oncology</i> , 2015, 8, 58.	6.9	191
23	An introduction to stratified medicine. <i>Drug Discovery Today</i> , 2015, 20, 1409-1413.	3.2	2
24	Effects of ophiopogonin B on the proliferation and apoptosis of SGC-7901 human gastric cancer cells. <i>Molecular Medicine Reports</i> , 2016, 13, 4981-4986.	1.1	29
25	High Tumor Vascular Endothelial Growth Factor Expression Is Associated With Poorer Clinical Outcomes in Resected T3 Gastric Adenocarcinoma. <i>American Journal of Clinical Pathology</i> , 2016, 146, 278-288.	0.4	5
26	Advances of Molecular Targeted Therapy in Gastric Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 125-134.	0.6	15
27	Anti-metastatic activity of fangchinoline in human gastric cancer AGS cells. <i>Oncology Letters</i> , 2017, 13, 655-660.	0.8	14
28	High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients. <i>British Journal of Cancer</i> , 2017, 116, 1177-1185.	2.9	46
29	Predictive biomarkers along gastric cancer pathogenetic pathways. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 417-425.	1.1	24
30	A novel non-ATP competitive FGFR1 inhibitor with therapeutic potential on gastric cancer through inhibition of cell proliferation, survival and migration. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2017, 22, 852-864.	2.2	9
31	The role of antiangiogenic agents in the treatment of gastric cancer. <i>Medicine (United States)</i> , 2017, 96, e6301.	0.4	8
32	Cancer-associated fibroblasts regulate the biological behavior of cancer cells and stroma in gastric cancer (Review). <i>Oncology Letters</i> , 2018, 15, 691-698.	0.8	22
33	Treatment-related severe and fatal adverse events with molecular targeted agents in the treatment of advanced gastric cancer: a meta-analysis. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2281-2287.	1.0	5
34	The function of Notch1 intracellular domain in the differentiation of gastric cancer. <i>Oncology Letters</i> , 2018, 15, 6171-6178.	0.8	5
35	Novel <i>AKT1</i> mutations associated with cell-cycle abnormalities in gastric carcinoma. <i>Personalized Medicine</i> , 2018, 15, 79-86.	0.8	8
36	Trastuzumab, not lapatinib, has therapeutic effects on Chinese patients with HER2-positive cholangiocarcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 477-479.	0.6	5
37	Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 659-671.	1.1	15
38	Nanomedicine in Gastric Cancer. <i>Current Clinical Pathology</i> , 2019, , 213-247.	0.0	0
39	Gastric Cancer In The Precision Medicine Era. <i>Current Clinical Pathology</i> , 2019, , .	0.0	2

#	ARTICLE	IF	CITATIONS
40	Quantitative Analysis of HER2 Amplification by Droplet Digital PCR in the Follow-Up of Gastric Cancer Patients Being Treated with Trastuzumab after Surgery. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-8.	0.7	11
41	Expression of Human epidermal growth factor receptor 2, Survivin, Enhancer of zeste homolog -2, Cyclooxygenase-2, p53 and p16 molecular markers in Gall bladder carcinoma. <i>Journal of Carcinogenesis</i> , 2021, 20, 7.	2.5	16
42	A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer. <i>BMC Cancer</i> , 2021, 21, 923.	1.1	11
43	Targeting receptor tyrosine kinases in gastric cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 4536.	1.4	51
44	Targeted therapy for advanced gastric cancer: A review of current status and future prospects. <i>World Journal of Gastrointestinal Oncology</i> , 2015, 7, 401.	0.8	23
45	Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2014, 7, 42-8.	0.8	40
46	URI promotes gastric cancer cell motility, survival, and resistance to adriamycin in vitro. <i>American Journal of Cancer Research</i> , 2016, 6, 1420-30.	1.4	7
47	Targeting Infiltrating Myeloid Cells in Gastric Cancer Using a Pretargeted Imaging Strategy Based on Bio-Orthogonal Diels-Alder Click Chemistry and Comparison with <sup>89</sup> Zr-Labeled Anti-CD11b Positron Emission Tomography Imaging. <i>Molecular Pharmaceutics</i> , 2022, 19, 246-257.	2.3	7
48	Design, synthesis, and cytotoxic activities of isaindigotone derivatives as potential anti-gastric cancer agents. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 1212-1226.	2.5	8
49	Gastric Cancer: A review of risk factors and new insights into treatment. <i>Current Cancer Therapy Reviews</i> , 2022, 18, .	0.2	1
50	Signaling pathways and therapeutic interventions in gastric cancer. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	54
51	Stromal CD10 expression in gastric adenocarcinoma. <i>Journal of Medicine and Life</i> , 2022, 15, 679-684.	0.4	0
52	Next-Generation Molecular Markers: Challenges, Applications and Future Perspectives. , 2019, , 494-530.		0